- Poster will highlight interim evaluation update of
photoimmunotherapy based on Alluminox™ platform using ASP-1929 in
combination with anti-PD-1
- Japanese treating
physicians will present a poster on the latest data on
photoimmunotherapy in clinical practice in Japan for recurrent nasopharyngeal
carcinoma
Disclaimer: Rakuten Medical's therapies based on
Alluminox™ platform are investigational outside of Japan.
SAN
DIEGO, May 9, 2024 /PRNewswire/ -- Rakuten
Medical, Inc., a global biotechnology company developing and
commercializing precision, cell-targeting photoimmunotherapy based
on its proprietary Alluminox™ platform, today announced that it
will present a poster at the 2024 American Society of Clinical
Oncology (ASCO) Annual Meeting (ASCO 2024), which will be held in
Chicago, Illinois from
May 31 through June 4, 2024.
The poster presentation will showcase the updated safety and
efficacy findings from an interim evaluation of Rakuten Medical's
open-label Phase 1b/2 study
(ASP-1929-181/ClinicalTrials.gov Identifier: NCT04305795) of
photoimmunotherapy using ASP-1929 in combination with anti-PD-1
therapy in recurrent or metastatic head and neck squamous cell
carcinoma.
Rakuten Medical will also have a booth in the Exhibit Hall. The
Company medical team will be pleased to welcome ASCO participants
at booth #12118.
Rakuten Medical's Poster Presentation
- Abstract Title: Recent safety and efficacy findings
from a phase 1b/2 open-label
combination study of ASP-1929 photoimmunotherapy with anti-PD-1
therapy in EGFR-expressing advanced head and neck squamous cell
carcinoma (HNSCC)
- Abstract Number: 6083
- Abstract
Link: https://meetings.asco.org/abstracts-presentations/234832
- Session Name: Poster Session – Head and Neck
Cancer
- Session Date: Sunday, June 2,
2024
- Session Time: 9:00 a.m. – 12:00 p.m., CDT
- First Author: David M. Cognetti, Department of
Otolaryngology – Head and Neck Surgery, Thomas
Jefferson University, US
- Location: Exhibit Hall A, Poster Board #399
Rakuten Medical Booth
- Location: Exhibit Hall A, Booth #12118
- Exhibit Date: Saturday – Monday, June 1 - 3, 2024
In addition, a research team of Japanese physicians will present
a poster on the latest findings from a multi-institutional
observation study evaluating the efficacy and safety of
photoimmunotherapy for recurrent nasopharyngeal cancer in clinical
practice in Japan.
Poster Presentation by Japanese Physicians
- Abstract Title: Photoimmunotherapy in
nasopharyngeal carcinoma recurrence
- Abstract Number: 6068
- Abstract
Link: https://meetings.asco.org/abstracts-presentations/234781
- Session Name: Poster Session – Head and Neck
Cancer
- Session Date: Sunday, June 2, 2024
- Session Time: 9:00 a.m. – 12:00 p.m., CDT
- First Author: Takeshi Shinozaki, Department of Head
and Neck Surgery, National Cancer Center Hospital East,
Japan
- Location: Exhibit Hall A, Poster Board #384
The full abstracts will be available on the ASCO Annual Meeting
website.
For more information and update, follow Rakuten Medical on
LinkedIn or visit Rakuten Medical's booth at ASCO 2024.
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is
a global biotechnology company developing and commercializing
precision, cell targeting therapies based on its proprietary
Alluminox™ platform, which, in pre-clinical studies, has been shown
to induce rapid and selective cell killing and tumor necrosis.
Alluminox therapies have not yet been approved outside of
Japan. Rakuten Medical is
committed to its mission to conquer cancer by delivering its
innovative treatments as quickly as possible to as many patients as
possible all over the world. The company has offices in 5
countries/regions, including the United
States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit
www.rakuten-med.com.
About Alluminox™ platform
The Alluminox™ platform is
an investigational technology platform based on a cancer therapy
called photoimmunotherapy, which was developed by Dr. Hisataka
Kobayashi and team from the National Cancer Institute in the
United States. Rakuten Medical is
developing the Alluminox platform as a technology consisting of a
drug, device, and other related components. The drug component of
the platform consists of a targeting moiety conjugated with one or
more dyes leading to selective cell surface binding. The device
component consists of a light source that locally illuminates the
targeted cells with light to transiently activate the
drug. Pre-clinical data have shown that this activation elicits
rapid and selective necrosis of targeted cells through a
biophysical process that compromises the membrane integrity of the
targeted cells. Therapies developed on the Alluminox platform may
also result in local and systemic innate and adaptive immune
activation due to immunogenic cell death of the targeted cancer
cells and/or the removal of targeted immunosuppressive cells within
the tumor microenvironment. Outside of Japan, Alluminox therapies
have not yet been approved by any regulatory authority.
About ASP-1929
Rakuten Medical's first pipeline drug
developed on its Alluminox™ platform is ASP-1929, an antibody-dye
conjugate comprised of the antibody cetuximab and IRDye®
700DX, a light activatable dye. ASP-1929 binds to epidermal growth
factor receptor (EGFR), a cancer antigen expressed in multiple
types of solid tumors, including head and neck, breast, lung,
colorectal, prostate and pancreatic cancers. After binding to
cancer cells, ASP-1929 is locally activated by illumination with
red light (690 nm), emitted by a laser device system to produce a
photochemical reaction. This reaction is believed to cause
damage to the membrane of cancer cells, leading to selective
necrosis of cancer cells. ASP-1929 has received Fast Track
designation from the U.S. Food and Drug Administration (FDA) in
January 2018, and is currently under
investigation in a global Phase 3 clinical trial for recurrent head
and neck cancer. In Japan,
ASP-1929 received marketing approval from the Japanese Ministry of
Health, Labor, and Welfare for unresectable locally advanced or
recurrent head and neck cancer in September
2020, under the Sakigake Designation System and the
Conditional Early Approval System. Outside of Japan, ASP-1929 has not yet been approved by
any regulatory authority.
Contact Us
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rakuten-medical-announces-poster-presentation-and-booth-exhibition-at-asco-2024-annual-meeting-302141840.html
SOURCE Rakuten Medical, Inc.